Abstract
Statins, inhibitors of 3-hydroxy-3-methylglutaryl-CoA are best known for their lipid-lowering effects but they also possess immunomodulatory properties that are, at least in part, independent of changes in serum cholesterol. Some recent clinical trials (eg. PROVE-IT) have shown that statins exert beneficial cardiovascular effects independently of the resultant level of LDL cholesterol. These “pleiotropic” effects seem to be due to inhibition of prenylation of several proteins such as the small GTP-binding proteins Ras and Rho, and to the disruption, or depletion, of cholesterol rich membrane micro-domains (membrane rafts). Through these pathways statins are able to modulate immune responses by modulating cytokine levels and by affecting the function of cells involved in both innate and adaptive responses. Over the past decade, a large number of studies reported a prominent role of inflammation and immune response in atherosclerosis, thus, the ability of statins to modulate immune-inflammatory processes could explain their cardiovascular beneficial effects beyond lipid-lowering effects. Moreover, various studies demonstrated beneficial effects of statins in inflammatory and auto-immune diseases, such as rheumatoid arthritis, multiple sclerosis, and others. The purpose of this review is to summarize clinical and experimental evidence of immunomodulatory properties of these drugs, highlighting their clinical and, thus, therapeutic implications.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Immunomodulator Activity of 3-Hydroxy-3-Methilglutaryl-CoA Inhibitors
Volume: 7 Issue: 4
Author(s): Costantino Smaldone, Salvatore Brugaletta, Vincenzo Pazzano and Giovanna Liuzzo
Affiliation:
Abstract: Statins, inhibitors of 3-hydroxy-3-methylglutaryl-CoA are best known for their lipid-lowering effects but they also possess immunomodulatory properties that are, at least in part, independent of changes in serum cholesterol. Some recent clinical trials (eg. PROVE-IT) have shown that statins exert beneficial cardiovascular effects independently of the resultant level of LDL cholesterol. These “pleiotropic” effects seem to be due to inhibition of prenylation of several proteins such as the small GTP-binding proteins Ras and Rho, and to the disruption, or depletion, of cholesterol rich membrane micro-domains (membrane rafts). Through these pathways statins are able to modulate immune responses by modulating cytokine levels and by affecting the function of cells involved in both innate and adaptive responses. Over the past decade, a large number of studies reported a prominent role of inflammation and immune response in atherosclerosis, thus, the ability of statins to modulate immune-inflammatory processes could explain their cardiovascular beneficial effects beyond lipid-lowering effects. Moreover, various studies demonstrated beneficial effects of statins in inflammatory and auto-immune diseases, such as rheumatoid arthritis, multiple sclerosis, and others. The purpose of this review is to summarize clinical and experimental evidence of immunomodulatory properties of these drugs, highlighting their clinical and, thus, therapeutic implications.
Export Options
About this article
Cite this article as:
Smaldone Costantino, Brugaletta Salvatore, Pazzano Vincenzo and Liuzzo Giovanna, Immunomodulator Activity of 3-Hydroxy-3-Methilglutaryl-CoA Inhibitors, Cardiovascular & Hematological Agents in Medicinal Chemistry 2009; 7 (4) . https://dx.doi.org/10.2174/187152509789541864
DOI https://dx.doi.org/10.2174/187152509789541864 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immunomodulatory Therapeutic Effects of Curcumin on M1/M2 Macrophage
Polarization in Inflammatory Diseases
Current Molecular Pharmacology MCP-1/CCL2 as a Therapeutic Target in Myocardial Infarction and Ischemic Cardiomyopathy
Inflammation & Allergy - Drug Targets (Discontinued) Cardiovascular Toxicity of Cyclooxygenase Inhibitors and Promising Natur a l Substitutes
Current Pharmaceutical Design Nitric Oxide Signaling and the Cross Talk with Prostanoids Pathways in Vascular System
Medicinal Chemistry Pro-Inflammatory Cytokines IL-1β and TNF-α are not Associated with Plasma Homocysteine Concentration in Alzheimer’s Disease
Current Alzheimer Research Molecular Targets of FoxP3+ Regulatory T Cells
Mini-Reviews in Medicinal Chemistry Homocysteine in Neurology: From Endothelium to Neurodegeneration
Current Nutrition & Food Science Thalidomide and Analogs as Anti-Inflammatory and Immunomodulator Drug Candidates
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Probiotics: From Functional Foods to Pharmaceutical Products
Current Pharmaceutical Biotechnology The Gut Mucosa as a Site for Induction of Regulatory T-Cells
Current Pharmaceutical Design Perspectives on the Use of Gene Therapy for Chronic Joint Diseases
Current Gene Therapy Phytotherapeutic and Natural Compound Applications for Age-Related, Inflammatory and Serious Eye Ailments
Current Molecular Pharmacology Nitrogen, Oxygen or Sulfur Containing Heterocyclic Compounds as Analgesic Drugs Used as Modulators of the Nitroxidative Stress
Mini-Reviews in Medicinal Chemistry Spectroscopic Studies of the Effects of Glycation of Human Serum Albumin on L-Trp Binding
Protein & Peptide Letters Lipoxin and Synthetic Lipoxin Analogs: An Overview of Anti- Inflammatory Functions and New Concepts in Immunomodulation
Inflammation & Allergy - Drug Targets (Discontinued) Role of Advanced Glycation End Products (AGEs) in Osteoporosis in Diabetes
Current Drug Targets The Imaging of Apoptosis with the Radiolabelled Annexin A5: A New Tool in Translational Research
Current Clinical Pharmacology Tyrosine Kinase Inhibitor as a new Therapy for Ischemic Stroke and other Neurologic Diseases: is there any Hope for a Better Outcome?
Current Neuropharmacology UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase- 6 (pp-GalNAc-T6): Role in Cancer and Prospects as a Drug Target
Current Cancer Drug Targets Vascular Inflammation in Cardiovascular Disease: Is Immune System Protective or Bystander?
Current Pharmaceutical Design